GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroBo Pharmaceuticals Inc (NAS:NRBO) » Definitions » Dividend Yield %

NeuroBo Pharmaceuticals (NeuroBo Pharmaceuticals) Dividend Yield % : 0.00% (As of May. 16, 2024)


View and export this data going back to 2016. Start your Free Trial

What is NeuroBo Pharmaceuticals Dividend Yield %?

As of today (2024-05-16), the Trailing Annual Dividend Yield of NeuroBo Pharmaceuticals is 0.00%.

The historical rank and industry rank for NeuroBo Pharmaceuticals's Dividend Yield % or its related term are showing as below:

NRBO's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.37
* Ranked among companies with meaningful Dividend Yield % only.

NeuroBo Pharmaceuticals's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00.

As of today (2024-05-16), the Forward Dividend Yield % of NeuroBo Pharmaceuticals is 0.00%.

NeuroBo Pharmaceuticals's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


NeuroBo Pharmaceuticals Dividend Yield % Historical Data

The historical data trend for NeuroBo Pharmaceuticals's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroBo Pharmaceuticals Dividend Yield % Chart

NeuroBo Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Dividend Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NeuroBo Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Dividend Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NeuroBo Pharmaceuticals's Dividend Yield %

For the Biotechnology subindustry, NeuroBo Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuroBo Pharmaceuticals's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuroBo Pharmaceuticals's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where NeuroBo Pharmaceuticals's Dividend Yield % falls into.



NeuroBo Pharmaceuticals Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


NeuroBo Pharmaceuticals  (NAS:NRBO) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


NeuroBo Pharmaceuticals Dividend Yield % Related Terms

Thank you for viewing the detailed overview of NeuroBo Pharmaceuticals's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuroBo Pharmaceuticals (NeuroBo Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
200 Berkeley Street, Office 19th Floor, Boston, MA, USA, 02116
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused primarily on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of nonalcoholic steatohepatitis (NASH), obesity, and type 2 diabetes (T2D): DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
Executives
James Patrick Tursi director 106 ASHLEY COURT, MOORESTOWN NJ 08057
Marshall H Woodworth officer: Acting Chief Financial Officer C/O NEUROBO PHARMACEUTICALS, INC., 545 CONCORD AVENUE, SUITE 210, CAMBRIDGE MA 02138
Mark A Glickman director C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Joseph Hooker officer: Interim CEO and President C/O NEUROBO PHARMACEUTICALS, INC., 200 BERKELEY ST, OFFICE 19TH FLOOR, BOSTON MA 02116
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
E&healthcare Investment Fund Ii 10 percent owner 16TH FLOOR, YEOKSAM I-TOWER, 326, TEHERAN-RO, GANGNAM-GU, SEOUL M5 06211
E&investment, Inc. 10 percent owner 16TH FLOOR, YEOKSAM I-TOWER, B/D 326, TEHERAN-RO, GANGNAM-GU, SEOUL M5 00000
Hyung Heon Kim director C/O DONG-A ST & DONG-A SOCIO GROUP, 64 CHEONHO DAERO, DONGDAEMUN-GU, SEOUL M5 00000
Andrew I Koven director 3 COLUMBUS CIRCLE, SUITE 1710, C/O ARALEZ PHARMACEUTICALS INC., NEW YORK NY 10019
Na Yeon Kim director, 10 percent owner C/O NEUROBO PHARMACEUTICALS, INC., 177 HUNTINGTON AVENUE, SUITE 1700, BOSTON MA 02115
Richard Kang director 9451 SUNNYFIELD COURT, POTOMAC MD 20854
D Gordon Strickland director C/O AMPEX CORPORATION, 1228 DOUGLAS AVENUE, REDWOOD CITY CA 94063
Ben Gil Price officer: CEO and President 8297 CHAMPIONS GATE BLVD. #444, CHAMPIONS GATE FL 33896
Akash Bakshi director, officer: SVP and COO 602 BAINBRIDGE STREET, FOSTER CITY CA 94404

NeuroBo Pharmaceuticals (NeuroBo Pharmaceuticals) Headlines